Provenance Wealth Advisors LLC Purchases 22,615 Shares of Pfizer Inc. $PFE

Provenance Wealth Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 132.4% in the third quarter, Holdings Channel.com reports. The fund owned 39,699 shares of the biopharmaceutical company’s stock after acquiring an additional 22,615 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Pfizer were worth $1,132,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of PFE. BlackRock Inc. lifted its stake in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. State Street Corp grew its position in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after purchasing an additional 5,364,929 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Pfizer during the 2nd quarter valued at $1,049,602,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after purchasing an additional 293,029 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. UBS Group increased their price objective on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Wednesday. HSBC boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Scotiabank raised their price target on Pfizer from $33.00 to $35.00 and gave the company a “sector outperform” rating in a report on Wednesday. Finally, Argus set a $40.00 price target on Pfizer in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $29.81.

Pfizer Trading Up 2.6%

Shares of PFE stock opened at $30.79 on Thursday. The business has a 50-day moving average price of $28.69 and a two-hundred day moving average price of $26.86. Pfizer Inc. has a 12-month low of $23.62 and a 12-month high of $31.06. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market cap of $175.52 billion, a P/E ratio of 43.99, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The company’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.6%. Pfizer’s dividend payout ratio is currently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS forecast to $2.95–$3.05, citing execution and cost savings. Reuters article
• Positive Sentiment: Growth in newer and acquired medicines is helping offset pandemic-product declines: these products grew 32% operationally in Q3, while non-COVID products overall grew 7%. This supports Pfizer’s effort to build growth beyond COVID sales. The Motley Fool article
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling further potential upside. Ticker Report article
• Neutral Sentiment: Pfizer named Cecile Guegan permanent CFO after she served in the interim role. The appointment provides leadership continuity, though its near-term financial impact is unclear. Business Wire announcement
• Negative Sentiment: COVID-related product sales continued to decline, and revenue was slightly lower year over year. UBS and Citi raised their targets to $30 and RBC to $28, but each retained a neutral or sector-perform rating—targets below the recent share price that may temper expectations. UBS rating

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.